


Apr 26, 2024

# Crystallization of Enterovirus coxsackievirus A16 2A protease

DOI

dx.doi.org/10.17504/protocols.io.3byl49kdzgo5/v1



ryan Lithgo<sup>1,2</sup>, Peter Marples<sup>1,2</sup>, Lizbé Koekemoer<sup>3</sup>, Daren Fearon<sup>1,2</sup>

<sup>1</sup>Diamond Light Source; <sup>2</sup>Research Complex at Harwell; <sup>3</sup>Centre of Medicines Discovery, University of Oxford ryan Lithgo: The principle crystallographer on the Coxsackievirus A16 project.;

**ASAP Discovery** 



Lizbé Koekemoer

University of Oxford

OPEN ACCESS



DOI: dx.doi.org/10.17504/protocols.io.3byl49kdzgo5/v1

**Protocol Citation:** ryan Lithgo, Peter Marples, Lizbé Koekemoer, Daren Fearon 2024. Crystallization of Enterovirus coxsackievirus A16 2A protease. **protocols.io** <a href="https://dx.doi.org/10.17504/protocols.io.3byl49kdzgo5/v1">https://dx.doi.org/10.17504/protocols.io.3byl49kdzgo5/v1</a>

**License:** This is an open access protocol distributed under the terms of the <u>Creative Commons Attribution License</u>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working We use this protocol and it's

working

Created: April 26, 2024

Last Modified: April 26, 2024

Protocol Integer ID: 98841

Keywords: crystallisation, XChem, ASAP, AViDD, CMD, Diamond Light Source, i04-1, Coxsackievirus, A16



Funders Acknowledgement: National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID) Grant ID: Grant ID: U19AI171399

## Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Acknowledgements:

Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot OX11 0QX, UK Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot OX11 0FA, UK Oxford Lab Technologies crystal shifter <a href="https://doi.org/10.1107/S2059798320014114">https://doi.org/10.1107/S2059798320014114</a>

## Abstract

Picornaviridae coxsackievirus A16 is the causative agent of paediatric hand-foot-and-mouth disease, and a target for pandemic preparedness due to the risk of higher order complications in a large-scale outbreak. The 2A protease of the virus is responsible for self-cleavage from the poly protein, allowing for correct folding and assembly of capsid proteins in the final stages of viral replication. Inhibition deranges capsid folding and assembly, preventing formation of mature virions in host cells and making the protease a valuable target for antiviral activity. This protocol was used to grow coxsackievirus A16 crystals that were applied high-throughput crystallographic fragment screening on the target.

#### **Materials**

### https://swissci.com/product/3-lens-crystallisation-plate/ Codes:

Midi: UVXPO-3LENS 3W96T-PS 3W96T-UVP

[M] 1 Molarity (M) MES 6.7 , Molecular Dimensions, Catalog # MD2-013-PH 6.7 50% w/v PEG 20000, Molecular Dimensions, Catalog # MD2-250-16

Purified SARS CoV-2 Coxsackievirus A16 protein ( [м] 20 mg/mL ) in [м] 10 millimolar (mM) HEPES, Сн 7.5 , гм] 0.5 Molarity (M) NaCl, 5% glycerol, гм] 0.5 millimolar (mM) TCEP

Protein construct <a href="https://www.addgene.org/204809/">https://www.addgene.org/204809/</a>



## Safety warnings




• Follow all handling warning for the chemicals used in the crystalllisation screen composition.



## Equipment needed

**Formulatrix Rock Imager** (or incubator of choice) **SPT mosquito** 




P100 8 multi-channel pipette

SwissCI 3 lens plate


## Crystallization experiment

2 Prepare seed stock:



1: 1000 dilution & Sample seeds

3 Protein and buffer requirements:



1d



Δ 14.4 μL Sample seeds, dilution 1:1000

4 Crystallisation screen composition:

13.5 % PEG 20000 [м] 0.1 Molarity (М) MES (р. 6.7

#### Stock solutions used:

[M] 1 Molarity (M) MES С 6.7 50% w/v PEG 20000

#### Note

The crystallisation screen can be stored in a duran bottle or aliquoted into 96 deep well block for easy dispensing into SwissCI 3 lens plates.

For long term storage keep the Crystallisation screen in the fridge at 4°C.

Dispense Δ 35 μL Crystallisation screen into SwissCl 3 lens plate reservoir wells using a 100 μl multi-channel pipette.

Dispense 🚨 150 nL [M] 20 mg/mL 🥻 Sample to each lens using the SPT mosquito.

Dispense  $\triangle$  150 nL Crystallisation screen to each lens using the SPT mosquito.

Final drop volume: 350 nl

6 Incubate at \$\colon 20 \colon C for 24:00:00 h in Formulatrix Rock Imager.

**Imaging Schedule**: The first images are taken after 12hrs and the imaging schedule follows a Fibonacci sequence of days for further collections.

7 Crystal typically form after ~24hrs

1d



## **Expected result**

Crystals typically reach their maximum size after ~24 h.


**Morphology:** typically rectangles.

Size:  $\sim$ 75 µm in length and  $\sim$ 10 µm in width, depth of the crystals is  $\sim$ 10 µm, giving a

rectangular appearance Average resolution: 1.6 Å

Space group: C2

**Unit cell:** 86 Å, 57 Å, 32 Å 90°, 95°, 90°



An example of a drop containing Coxsackievirus A16 crystals.



## Data collection at Synchrotron

8 Diamond Light Source

> **Unattended Data Collection (UDC) Data Collection Temperature:** 100K **Detector: DECTRIS EIGER2 X 9M**

**Beamline:** 104-1

Wavelength: 0.9212 Å Resolution (Å): 1.21 **Beam Size (µm):** 60 X 50 Number of images: 3600

Oscillation: 0.10° **Exposure (s):** 0.0020 Transmission (%): 100 Flux (ph/s): 9.50e+11

## Protocol references

N/A